Full-Time
Pharmaceutical Sales Account Representative
Updated on 9/3/2026
Prism Biotech
Prelaunch prescriber profiling and targeting
Compensation Overview
$87.3k - $120.5k/yr
Daytona Beach, FL, USA
In Person
Bachelor's
 Sales & Account Management (1) |
|---|
Get referred to Prism Biotech
See people who can refer or advise you
- Ability to quickly build meaningful relationships.
- Ability to thrive and adapt in ambiguous pharmaceutical sales environments.
- Strong clinical selling and account management skills.
- Strong verbal and written communication skills.
- Ability to work and lead collaboratively while putting integrity first.
- Uphold and model competencies key to the organization's culture, including integrity, drive, accountability, flexibility, and perseverance.
- Meet or exceed assigned territory pharmaceutical sales goals.
- Use analytical and business acumen skills to identify opportunities and provide actionable recommendations and solutions to increase product growth.
- Maximize new business opportunities and develop and grow the pharmaceutical market.
- Communicate competitive market intelligence to brand teams and management.
- Collaborate cross-functionally with Division Business Managers, Regional Business Directors, and corporate commercial teams.
- Comply with corporate and pharmaceutical sales legal requirements for product promotion, sampling, and resource tracking.
- Develop local opinion leader relationships to achieve aligned objectives.
- A relevant degree or documented sales experience.
Prism Biotech provides field sales and medical affairs services to support pharmaceutical launches. It deploys pharmaceutical sales reps and medical science liaisons before product approval to collect prescriber information through office visits. The data gathered is combined with existing records to create a profile of key prescriber targets and disease states. This profiling happens before a launch so the sales team is prepared with identified targets and relevant physician insights. Prism Biotech differentiates itself by offering a full-service prelaunch target physician profiling workflow, aligning early market intelligence with product planning. The company’s goal is to prime and ready the sales force with accurate, ready-to-target physician profiles ahead of a brand’s approval and launch.
Company Size
N/A
Company Stage
N/A
Total Funding
N/A
Headquarters
Upper Merion Township, Pennsylvania
Founded
2019
Get referred to Prism Biotech
See people who can refer or advise you
Simplify's Take
What believers are saying
- Ono paid PRISM a milestone in November 2025, validating PepMetics execution.
- E7386 Phase 1 results were published in January 2026, extending clinical credibility.
- March 2026 Receptor.AI deal adds AI-driven discovery leverage for difficult targets.
What critics are saying
- August 2026 nine-month loss widened to ¥845.7 million; burn remains heavy.
- Servier terminated its collaboration in October 2025, proving partner churn hits PRISM.
- September 2026 cash burn and no guidance set up a dilutive 2027 financing crunch.
What makes Prism Biotech unique
- PepMetics targets intracellular protein-protein interactions, a hard, scarce drug-discovery niche.
- PRISM BioLab monetizes by out-licensing programs to Eisai, Ono, and Servier.
- 2026 collaborations with Receptor.AI and Talus deepen platform optionality.
Help us improve and share your feedback! Did you find this helpful?